Allena Pharmaceuticals logo
Allena Pharmaceuticals ALNA

Quarterly report 2022-Q2
added 08-15-2022

report update icon

Allena Pharmaceuticals Net Debt 2011-2026 | ALNA

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Allena Pharmaceuticals

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-29.5 M -21.2 M -20 M -51.7 M -85.1 M -15.7 M -62.8 M - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-15.7 M -85.1 M -40.8 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
AbbVie AbbVie
ABBV
59.5 B $ 208.84 -2.86 % $ 369 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
14.7 M $ 3.52 0.28 % $ 1.05 B canadaCanada
Grifols, S.A. Grifols, S.A.
GRFS
5.36 B $ 8.24 -0.12 % $ 6.83 B spainSpain
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-195 M $ 229.25 0.44 % $ 5 B danmarkDanmark
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
166 M $ 74.21 -2.3 % $ 1.43 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-32.7 M $ 1.41 2.17 % $ 375 M britainBritain
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
-5.52 M $ 1.51 48.04 % $ 17 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-31.2 M - 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
-1.3 B $ 55.5 -3.04 % $ 10.6 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
-206 M $ 8.03 2.29 % $ 220 M israelIsrael
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
65 M $ 14.81 2.63 % $ 2.25 B usaUSA
Altimmune Altimmune
ALT
-9.22 M $ 3.34 7.05 % $ 294 M usaUSA
BioNTech SE BioNTech SE
BNTX
-973 M $ 91.18 1.97 % $ 27.2 B germanyGermany
Amgen Amgen
AMGN
41 B $ 347.94 -1.51 % $ 187 B usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
-26.8 M $ 15.61 0.9 % $ 2.1 B canadaCanada
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
32.8 B $ 59.6 -2.45 % $ 121 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
-135 M $ 4.14 -2.59 % $ 683 M britainBritain
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
211 M $ 9.02 -3.84 % $ 1.86 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.13 K - -52.27 % $ 4.45 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
-63.1 M $ 5.76 1.95 % $ 469 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-3.56 B - 0.49 % $ 251 B cayman-islandsCayman-islands
AVROBIO AVROBIO
AVRO
-76.6 M - 1083.1 % $ 745 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
-206 M $ 3.41 1.19 % $ 116 M franceFrance
Biogen Biogen
BIIB
3.36 B $ 177.34 -3.5 % $ 26 B usaUSA
Axcella Health Axcella Health
AXLA
1.5 M - -16.42 % $ 249 M usaUSA
Axon Enterprise Axon Enterprise
AXON
-404 M $ 412.81 -2.54 % $ 31.3 B usaUSA